Skip to main content

64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.

Publication ,  Journal Article
Lee, H; Shields, AF; Siegel, BA; Miller, KD; Krop, I; Ma, CX; LoRusso, PM; Munster, PN; Campbell, K; Gaddy, DF; Leonard, SC; Geretti, E ...
Published in: Clin Cancer Res
August 1, 2017

Purpose: Therapeutic nanoparticles are designed to deliver their drug payloads through enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and its variability in human tumors is highly debated and has been proposed as an explanation for variable responses to therapeutic nanoparticles in clinical studies.Experimental Design: We assessed the EPR effect in patients using a 64Cu-labeled nanoparticle, 64Cu-MM-302 (64Cu-labeled HER2-targeted PEGylated liposomal doxorubicin), and imaging by PET/CT. Nineteen patients with HER2-positive metastatic breast cancer underwent 2 to 3 PET/CT scans postadministration of 64Cu-MM-302 as part of a clinical trial of MM-302 plus trastuzumab with and without cyclophosphamide (NCT01304797).Results: Significant background uptake of 64Cu-MM-302 was observed in liver and spleen. Tumor accumulation of 64Cu-MM-302 at 24 to 48 hours varied 35-fold (0.52-18.5 %ID/kg), including deposition in bone and brain lesions, and was independent of systemic plasma exposure. Computational analysis quantified rates of deposition and washout, indicating peak liposome deposition at 24 to 48 hours. Patients were classified on the basis of 64Cu-MM-302 lesion deposition using a cut-off point that is comparable with a response threshold in preclinical studies. In a retrospective exploratory analysis of patient outcomes relating to drug levels in tumor lesions, high 64Cu-MM-302 deposition was associated with more favorable treatment outcomes (HR = 0.42).Conclusions: These findings provide important evidence and quantification of the EPR effect in human metastatic tumors and support imaging nanoparticle deposition in tumors as a potential means to identify patients well suited for treatment with therapeutic nanoparticles. Clin Cancer Res; 23(15); 4190-202. ©2017 AACR.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

August 1, 2017

Volume

23

Issue

15

Start / End Page

4190 / 4202

Location

United States

Related Subject Headings

  • Trastuzumab
  • Spleen
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Positron Emission Tomography Computed Tomography
  • Polyethylene Glycols
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Nanoparticles
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lee, H., Shields, A. F., Siegel, B. A., Miller, K. D., Krop, I., Ma, C. X., … Hendriks, B. S. (2017). 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clin Cancer Res, 23(15), 4190–4202. https://doi.org/10.1158/1078-0432.CCR-16-3193
Lee, Helen, Anthony F. Shields, Barry A. Siegel, Kathy D. Miller, Ian Krop, Cynthia X. Ma, Patricia M. LoRusso, et al. “64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.Clin Cancer Res 23, no. 15 (August 1, 2017): 4190–4202. https://doi.org/10.1158/1078-0432.CCR-16-3193.
Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2017 Aug 1;23(15):4190–4202.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

August 1, 2017

Volume

23

Issue

15

Start / End Page

4190 / 4202

Location

United States

Related Subject Headings

  • Trastuzumab
  • Spleen
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Positron Emission Tomography Computed Tomography
  • Polyethylene Glycols
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Nanoparticles
  • Middle Aged